

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2 of 3

Complete if Known

Application Number	10/822,568
Filing Date	April 12, 2004
First Named Inventor	Thunder Jalili
Group Art Unit	1614
Examiner Name	To be assigned
Attorney Docket Number	0274-5928 IIS

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/FC/		AVIRAM et al., Pomegranate juice consumption inhibits serum angiotensin converting enzyme activity and reduces systolic blood pressure, Atherosclerosis, 2001, pp. 195-98; Vol. 158.	
		BRODY et al., A randomized controlled trial of high dose ascorbic acid for reduction of blood pressure, cortisol, and subjective responses to psychological stress, Psychopharmacology, 2002, pp. 319-24, Vol. 159.	
		Quarte DURANTE et al., Antihypertensive effects of the flavonoid quercetin in spontaneously hypertensive rats, British Journal of Pharmacology, 2001, pp. 117-24, Vol. 133.	
		GALLEY et al., Combination oral antioxidant supplementation reduces blood pressure, Clinical Science, 1997, pp. 361-65, Vol. 92.	
		GRAEFE et al., Pharmacokinetics and Bioavailability of Quercetin Glycosides in Humans, Herbal Medicine, 2001, pp. 492-99, Vol. 41.	
		JALILI et al., PKC translocation without changes in Galphaq and PLC-beta protein abundance in cardiac hypertrophy and failure, American Physiological Society, pp. H2298-H2304.	(1999)
		KOBA et al., Effects of alpha-Tocopherol and Tocotrienols on Blood Pressure and Linoleic Acid Metabolism in the Spontaneously Hypertensive Rat (SHR), Biosci. Biotech. Biochem., 1992, pp. 1420-23, Vol. 56, No. 9.	
		NAGUIB, A Fluorometric Method for Measurement of Oxygen Radical-Scavenging Activity of Water-Soluble Antioxidants, Analytical Biochemistry, 2000, pp. 93-98, Vol. 284.	
		NEWAZ et al., Effect of gamma-Tocotrienol on Blood Pressure, Lipid Peroxidation and Total Antioxidant Status in Spontaneously Hypertensive Rats (SHR), Clin. and Exper. Hypertension, 1999, pp. 1297-1313, Vol. 21, No. 8.	
		MAKITA et al., Alterations of phosphoinositide-specific phospholipase C and protein kinase C in the myocardium of spontaneously hypertensive rats, Basic Research in Cardiology, 1990, pp. 435-43, Vol. 85.	
		MELINA et al., Prevalence of Left Ventricular Hypertrophy and Cardiac Arrhythmias in Borderline Hypertension, American Journal of Hypertension, 1992, pp. 570-73, Vol. 5.	
		OKAMOTO et al., Development of a Strain of Spontaneously Hypertensive Rats, March 1963, Japanese Circulation Journal, pp. 282-93, Vol. 27.	
/FC/		PEDRO-BOTET et al., Decreased endogenous antioxidant enzymatic status in essential hypertension, Journal of Human Hypertension, 2000, pp. 343-45, Vol. 14.	

Examiner
Signature

/Frank Choi/

Date
Considered

10/01/2007

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 3 of 3

Complete if Known

Application Number	10/822,568
Filing Date	April 12, 2004
First Named Inventor	Thunder Jalili
Group Art Unit	1614
Examiner Name	To be assigned
Attorney Docket Number	0274-5928 IJIS

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/FC/		RIZZONI et al., Vascular Structural and Functional Alterations Before and After the Development of Hypertension in SHR, The American Journal of Hypertension, Ltd., 1994, pp. 193-200, Vol. 7.	
		ROBA, The Use of Spontaneously Hypertensive Rats for the Study of Anti-Hypertensive Agents, Laboratory Animal Science, 1976, pp. 305-18, Vol. 26, No. 2.	
		TAKEISHI et al., Src and Multiple MAP Kinase Activation in Cardiac Hypertrophy and Congestive Heart Failure Under Chronic Pressure-overload: Comparison with Acute Mechanical Stretch, 2001, J. Mol. Cell Cardiol., pp. 1637-48, Vol. 33.	
		VAZIRI et al., Effect of Antioxidant Therapy on Blood Pressure and NO Synthase Expression in Hypertensive Rats, December 2000, pp. 957-964.	
		VAZIRI et al., Increased nitric oxide inactivation by reactive oxygen species in lead-induced hypertension, Kidney International, 1999, pp. 1492-98, Vol. 56.	
/FC/		VAZIRI et al., Induction of Oxidative Stress by Glutathione Depletion Causes Severe Hypertension in Normal Rats, Hypertension, 2000, pp. 142-46, Vol. 36.	

Examiner
Signature

/Frank Choi/

Date
Considered

10/01/2007

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**